Get the Daily Brief
Latest Biotech News
Nanoparticles program CAR T cells in vivo: Johns Hopkins demos systemic B-cell depletion
Johns Hopkins researchers reported a pair of preclinical advances showing that targeted, biodegradable nanoparticles can reprogram T cells inside living animals to express therapeutic receptors....
Scientists quantify LNP endosomal escape in vivo – a design tool for RNA therapeutics
Two Nature Biotechnology reports delivered complementary methods to measure lipid nanoparticle (LNP) performance inside animals, providing quantitative readouts of endosomal escape—a bottleneck...
Stealth DNA donors enable kilobase insertions... labs report safer, recombinase-compatible donors
Researchers announced new ‘immune-evasive’ donor DNA formats that permit safe, non-viral insertion of kilobase-scale payloads in vivo, addressing a major hurdle for scalable gene writing. Teams...
Amino acid boost improves LNP delivery... new tools sharpen liver targeting
Two independent studies reported actionable improvements to lipid nanoparticle (LNP) therapeutics: a simple amino acid cocktail that markedly increases mRNA and CRISPR editing efficiency, and an...
Ultragenyx gene therapy meets co‑primary endpoint in phase 3: midtrial win
Ultragenyx reported that its gene therapy hit a co‑primary endpoint in the mid‑point analysis of a Phase 3 study for a rare urea cycle disorder, producing a statistically significant reduction in...
Muscle therapies advance: Regenxbio posts clean DMD safety; BridgeBio muscle drug shows phase‑3 efficacy
Two muscular-disease programs reported encouraging clinical and safety data this week. Regenxbio disclosed a clean safety profile and functional improvements for its Duchenne muscular dystrophy...
RNA‑to‑heart spinout lands $270M; Vima expands to $100M... cardiac and movement disorder bets draw capital
A new precision-cardiology spinout (Atrium Therapeutics) raised or received $270 million in cash and equivalents to develop antibody-oligonucleotide conjugates (AOCs) and RNA drugs targeting rare...
Lilly escalates compounder fight: impurity flagged in vitamin‑B12‑spiked tirzepatide
Eli Lilly publicly urged regulatory action after internal testing found an impurity forming when tirzepatide (the active ingredient in Zepbound/Mounjaro) was combined with vitamin B12 in...
FDA consolidates adverse‑event trackers: single system for drug and vaccine safety
The U.S. Food and Drug Administration announced plans to merge its patchwork of adverse event (AE) reporting systems into a unified platform, aiming to improve detection of safety signals across...
HIV diagnostics push: Bioneer gains CE‑IVDR for HIV‑1 quant kit; Gates backs Altratech POC viral‑load test
Two diagnostic developments signaled momentum for scalable HIV monitoring. South Korea’s Bioneer secured EU IVDR Class D certification for its AccuPower HIV‑1 Quant Kit on an automated ExiStation...
Nanoparticles generate CAR T cells in vivo – Johns Hopkins shows mouse proof
Johns Hopkins researchers reported an mRNA-loaded nanoparticle that programs a patient’s T cells to express an anti-CD19 chimeric antigen receptor (CAR) inside the body, producing functional CAR T...
Stealth DNA circles enable kilobase gene insertion... a safer route to big edits
Researchers led by Ben Kleinstiver developed a circular single-stranded DNA donor (INSTALL) that supports kilobase-scale genome insertions while evading cytosolic DNA sensors that trigger toxic...
New in vivo assays quantify LNP endosomal escape — a delivery bottleneck solved
Two Nature Biotechnology reports introduced orthogonal in vivo assays to quantify endosomal escape of lipid nanoparticles (LNPs), identifying lipid chemistries and formulations that improve...
Vertex files BLA after Rainier win — IgAN proteinuria plunges in Phase III
Vertex signaled a registration push for povetacicept after Phase III Rainier data showing a marked reduction in proteinuria. Interim results reported a ~52% reduction in urine...
Lilly bets $3bn on China production – doubles down on Asia supply
Eli Lilly announced a $3 billion investment to expand oral solid-dose manufacturing in China to support upcoming launches, including its obesity candidate orforglipron, and pledged $500 million to...
Lilly warns of impurity risk — compounders squeeze GLP-1 pricing
Eli Lilly warned that compounded versions of tirzepatide-based products that include vitamin B12 additives may introduce safety risks, highlighting impurity and formulation concerns as telehealth...
FDA consolidates adverse-event trackers: one database for safety signals
The U.S. Food and Drug Administration announced a consolidation of its patchwork adverse-event reporting systems into a single Adverse Event Monitoring System. Agency statements and reporting...
$270m spinout targets RNA delivery to the heart — Atrium formed from Avidity assets
Atrium Therapeutics launched with roughly $270 million after Novartis carved out Avidity Biosciences’ precision cardiology programs. The spinout inherited Avidity’s Antibody–Oligonucleotide...
Optical genome mapping spots extra actionable variants in ~20% of acute leukemias
A Canadian tertiary-care study found optical genome mapping (OGM) identified additional clinically relevant structural variants in nearly 20% of acute leukemia cases when used as a first-line...
CMS proposes wider coverage for CRC biomarker tests — age lowered, bar raised
The Centers for Medicare & Medicaid Services proposed revising its National Coverage Determination for non-invasive colorectal cancer (CRC) screening tests: expanding coverage to beneficiaries...